At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Nov 12, 2026 at 18:44 ET
Two insiders at Rocket Pharmaceuticals sold a combined $139K in open-market sales within days of the Q3 2026 earnings release. The sales are small relative to the $272M market cap (0.05%) and are not under 10b5-1 plans, but the dollar amount is below the materiality threshold for a bearish signal.
- General Counsel sold 53.4K shares at $2.39 for $128K on 2026-11-05 (open-market, no 10b5-1 plan)
- See Remarks insider sold 4.9K shares at $2.33 for $11K on 2026-11-09 (open-market, no 10b5-1 plan)
- Total open-market sales: $139K, representing 0.05% of $272M market cap
- Sales occurred 1-7 days before the Q3 2026 earnings release on 2026-11-12
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access